Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13600126 | 0.83 | NPC1 (0.41) | NPC1RAB9ACA12CA9OPRM1 | |
| SCHEMBL15111158 | 0.72 | OPRM1 (0.51) | NPC1RAB9ACA12CA9OPRM1 | |
| SCHEMBL25430875 | 0.71 | MMP1 (0.43) | NPC1RAB9ANAMPTCA12CA9 | |
| SCHEMBL4445072 | 0.70 | NPC1 (0.41) | NPC1RAB9ANAMPTCA12CA9 | |
| SCHEMBL24737421 | 0.69 | OPRM1 (0.44) | OPRM1OPRL1MAOAMAOBLMNA | |
| SCHEMBL968919 | 0.69 | NPC1 (0.67) | NPC1RAB9ACA12CA9 | |
| SCHEMBL13600125 | 0.68 | OPRM1 (0.43) | OPRM1OPRL1MAOAMAOBLMNA | |
| SCHEMBL27805826 | 0.67 | OPRM1 (0.45) | NPC1RAB9ACA12CA9OPRM1 | |
| SCHEMBL19027679 | 0.67 | ALDH1A1 (0.65) | NPC1RAB9ACA12CA9LMNA | |
| SCHEMBL19027677 | 0.66 | OPRM1 (0.54) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | NPC1 3357/4885RAB9A 732/4885NAMPT 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.